HK Stock Market Move | Asymchem Laboratories (06821) rose nearly 3% in the morning. Recently, Asymchem Laboratories' biological Shanghai Fengxian base has officially started production, with a focus on laying out areas such as NDCs for drug development.

Asymchem Laboratories (06821) rose nearly 3% in the morning, rising 2.05% to HK$79.65 as of the time of writing, with a turnover of HK$15.5175 million. In terms of news, recently, according to Asymchem Laboratories official WeChat account, the commercial production base of Asymchem Laboratories Biologics in Fengxian, Shanghai has been officially put into operation. This base is another key commercial production base established by Asymchem Laboratories Biologics after the Jinshan base in Shanghai and the Zhangjiang Science and Technology Center, which can help customers accelerate commercial production. The commercial operation of the Fengxian base signifies a significant upgrade for Asymchem Laboratories Biologics in the biopharmaceutical CDMO field. The Fengxian base has a total planned construction area of over 130,000 square meters, focusing on biologics such as ADCs (Novel Drug Conjugates), antibodies/TCE, and recombinant proteins. The commercial production capacity for antibodies (Phase I A) adopts advanced automation systems and production equipment, with 200L/500L/2000L disposable bioreactor production lines, and a 20m freeze dryer, capable of undertaking IND and post-commercialization projects. The commercial production capacity for NDCs (Phase I B) is expected to start commercial operation in January 2026, equipped with 100L-200L-500L coupling reactors and 10m + 15m + 2x20m freeze dryers to rapidly and flexibly meet customer production needs.